Showing 3091-3100 of 7016 results for "".
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
https://reachmd.com/programs/cme/nsclc-data-review-efficacy-and-safety-data-for-on-state-ras-inhibitors/54121/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Innovations in Precision Medicine: Leveraging Guideline-Based Immunotherapy and Targeted Treatments in Gynecologic Oncology
https://reachmd.com/programs/cme/Innovations-in-Precision-Medicine-Leveraging-Guideline-Based-Immunotherapy-and-Targeted-Treatments-in-Gynecologic-Oncology/37235/Multidisciplinary experts explore biomarker-driven strategies, immunotherapy, and personalized care in cervical and endometrial cancer management.The Potential Impact of RCC Molecular Subtypes on Treatment Outcomes
https://reachmd.com/programs/project-oncology/the-potential-impact-of-rcc-molecular-subtypes-on-treatment-outcomes/26533/Tune in to hear expert insights on recent research investigating if renal cell carcinoma molecular subtypes impact treatment outcomes.Advances in DMD Care: Evaluating a Gene Therapy’s Efficacy and Safety
https://reachmd.com/programs/neurofrontiers/advances-in-dmd-care-evaluating-a-gene-therapys-efficacy-and-safety/26327/Explore the efficacy and safety data that led to the expanded approval of a gene therapy for patients with Duchenne muscular dystrophy.Rosacea: A Closer Look at the Latest Treatment Options
https://reachmd.com/programs/practical-dermatology/rosacea-a-closer-look-at-the-latest-treatment-options/23983/The latest treatments and expanded, responsible choices for treating patients with rosacea.Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
https://reachmd.com/programs/cme/contrasting-trop2-targeted-adcs-in-breast-cancer-therapy/33024/Compare TROP2-targeted ADCs for mBC by molecular structure, patient eligibility, and clinical evidence to guide patient-centered treatment strategiesAdvancing Care: Clinical Innovations on the Horizon
https://reachmd.com/programs/cme/advancing-care-clinical-innovations-on-the-horizon/35881/Learn about LGMD2I/R9—genetics, diagnosis, treatment, clinical trials, and care gaps—in this expert-led, comprehensive educational video series.Mind Matters: Psychiatric Comorbidity in the Prodromal Phase of MS
https://reachmd.com/programs/neurofrontiers/mind-matters-psychiatric-comorbidity-in-the-prodromal-phase-of-ms/16269/A recent study investigated if psychiatric conditions can be an early predictor of MS. Let's dive into the findings.ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
https://reachmd.com/programs/cme/elevate-elacestrant-plus-capivasertib-in-advanced-breast-cancer/57227/Watch our experts review key ASCO 2026 data on oral SERD therapies in breast cancer and discuss the potential impact on treatment sequencing and patient care.Time to Recurrence and Early Risk Indicators in BRVO-Related Macular Edema
https://reachmd.com/programs/eye-on-ocular-health/time-to-recurrence-and-early-risk-indicators-in-brvo-related-macular-edema/54481/